Yhdysvallat - englanti - NLM (National Library of Medicine)

a-s medication solutions - neisseria meningitidis group a capsular polysaccharide tetanus toxoid conjugate antigen (unii: t4gyx3110d) (neisseria meningitidis group a capsular polysaccharide tetanus toxoid conjugate antigen - unii:t4gyx3110d), neisseria meningitidis group c capsular polysaccharide tetanus toxoid conjugate antigen (unii: zt89e5a103) (neisseria meningitidis group c capsular polysaccharide tetanus toxoid conjugate antigen - unii:zt89e5a103), neisseria meningitidis group y capsular polysaccharide tetanus toxoid conjugat - menquadfi® is a vaccine indicated for active immunization for the prevention of invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. menquadfi is indicated for use in individuals 2 years of age and older. menquadfi does not prevent n. meningitidis serogroup b disease. severe allergic reaction to any component of the vaccine, or after a previous dose of menquadfi or any other tetanus toxoid-containing vaccine [see description (11) ]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to menquadfi during pregnancy. to enroll in or obtain information about the registry, call sanofi pasteur at 1-800-822-2463. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. there are no clinical studies of menquadfi

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

nuron biotech b.v. - neisseria meningitidis serogroup c (strain c11) polysaccharide, corynebacterium diphtheriae crm197 carrier protein, aluminium phosphate - solution for injection - 0.5 millilitre - meningococcal vaccines

Kanada - englanti - Health Canada

pfizer canada ulc - neisseria meningitidis grp b recombinant lipoprotein 2086 subfamily a; neisseria meningitidis grp b recombinant lipoprotein 2086 subfamily b - suspension - 60mcg; 60mcg - neisseria meningitidis grp b recombinant lipoprotein 2086 subfamily a 60mcg; neisseria meningitidis grp b recombinant lipoprotein 2086 subfamily b 60mcg - vaccines

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - neisseria meningitidis group c strain c11 capsular polysaccharide tetanus toxoid conjugate; haemophilus influenzae type b polysaccharide tetanus toxoid conjugate - powder and solvent for solution for injection

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - neisseria meningitidis serogroup b fhbp subfamily b fusion protein; neisseria meningitidis serogroup b fhbp subfamily a fusion protein - suspension for injection

Singapore - englanti - HSA (Health Sciences Authority)

pfizer private limited - neisseria meningitidis serogroup b recombinant lp2086 subfamily a protein; neisseria meningitidis serogroup b recombinant lp2086 subfamily b protein - injection, suspension - neisseria meningitidis serogroup b recombinant lp2086 subfamily a protein 0.06 mg/0.5ml; neisseria meningitidis serogroup b recombinant lp2086 subfamily b protein 0.06 mg/0.5ml

Australia - englanti - Department of Health (Therapeutic Goods Administration)

integrated sciences pty ltd - ct793 - neisseria ivds - allplex ng & dr assay is a qualitative in vitro diagnostic test for single or multiple detection of n. gonorrhoeae (ng) and the mutation of a2059g and c2611t in the 23s rrna gene responsible for azithromycin resistance in n. gonorrhoeae (ng), and s91f in the gyrase a responsible for ciprofloxacin resistance in n. gonorrhoeae (ng)

Kanada - englanti - Health Canada

merck canada inc - haemophilus influenzae type b-prp; neisseria meningitidis outer membrane protein complex - suspension - 7.5mcg; 125mcg - haemophilus influenzae type b-prp 7.5mcg; neisseria meningitidis outer membrane protein complex 125mcg - vaccines

Kanada - englanti - Health Canada

sanofi pasteur limited - meningococcal polysaccharide antigen group a; meningococcal polysaccharide antigen group c; meningococcal polysaccharide antigen group y; meningococcal polysaccharide antigen group w-135 - powder for solution - 500mcg; 500mcg; 500mcg; 500mcg - meningococcal polysaccharide antigen group a 500mcg; meningococcal polysaccharide antigen group c 500mcg; meningococcal polysaccharide antigen group y 500mcg; meningococcal polysaccharide antigen group w-135 500mcg - vaccines

Kanada - englanti - Health Canada

sanofi pasteur limited - meningococcal polysaccharide antigen group a; meningococcal polysaccharide antigen group c; meningococcal polysaccharide antigen group y; meningococcal polysaccharide antigen group w-135 - kit - 50mcg; 50mcg; 50mcg; 50mcg - meningococcal polysaccharide antigen group a 50mcg; meningococcal polysaccharide antigen group c 50mcg; meningococcal polysaccharide antigen group y 50mcg; meningococcal polysaccharide antigen group w-135 50mcg - vaccines